Pacira BioSciences Defends Board Nominees Ahead of June Shareholder Vote

Event summary

  • Pacira BioSciences sent a letter to stockholders on May 12, 2026, urging votes for its three board nominees ahead of the June 9, 2026, annual meeting.
  • The company highlights its nominees' expertise in executive leadership, M&A, R&D, and commercialization to support its 5x30 growth strategy.
  • Pacira criticizes DOMA's nominees as underqualified, lacking biopharmaceutical industry experience and public company board service.
  • DOMA proposes a cost-cutting plan, pipeline discontinuation, and potential sale of the company, which Pacira warns could lead to value destruction.
  • Pacira's board recommends voting only for its nominees using the BLUE proxy card.

The big picture

Pacira's defense of its board nominees underscores a broader industry trend of activist investor pressure on biopharmaceutical companies to prioritize short-term financial gains over long-term innovation. The proxy fight highlights the strategic divide between Pacira's focus on sustainable growth through its 5x30 plan and DOMA's push for immediate cost reductions and potential sale, reflecting differing views on value creation in the sector.

What we're watching

Governance Dynamics
Whether Pacira's current board can maintain strategic direction against DOMA's disruptive campaign.
Execution Risk
The pace at which Pacira's 5x30 strategy delivers tangible results to counter DOMA's value destruction claims.
Investor Sentiment
How stockholders balance Pacira's long-term growth plan against DOMA's immediate cost-cutting and sale proposals.